The HELIOSTAR™ Balloon Ablation Catheter’s unique one-shot balloon technology enables pulmonary vein isolation in 12 seconds, with customized energy delivery and one integrated 3D mapping solution1
IRVINE, Calif., Oct. 13, 2022 /PRNewswire/ — Biosense Webster, Inc., part of Johnson & Johnson MedTech†, today announced the European launch of the HELIOSTAR™ Balloon Ablation Catheter – the first radiofrequency balloon ablation catheter. The HELIOSTAR™ Balloon Ablation Catheter is indicated for use in catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria and, when used with a compatible multi-channel RF generator, for cardiac ablation.
Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9093651-biosense-webster-launches-heliostar-radiofrequency-balloon-ablation-catheter/
Europe is home to more than 11 million people living with atrial fibrillation (AF); 2 by 2030, the number of people with AF is expected to increase by up to 70%.3 In Europe, catheter ablation is a recommended first-line treatment option‡4 and is associated with a significant improvement in quality of life and significant reductions in AF burden and AF-related complications.5,6,7
The HELIOSTAR™ Balloon Ablation Catheter is fully integrated with the CARTO™ 3 System, a 3D mapping solution. The HELIOSTAR™ Balloon Ablation Catheter has a compliant balloon that can conform to varied pulmonary vein…
